top of page

Moonwalk Biosciences raises $57 million today to pursue epigenome engineering

Co-Founder and CEO Alex Aravanis describes how epigenetic engineering could have advantages over gene editing and why he thinks Moonwalk's 'complete view' of the epigenome could give it an edge in this space.



Join the BiotechTV mailing list

Thanks for subscribing!

bottom of page